Cardiac transplantation for ischemic heart disease

Robroy H. MacIver, Edwin C. McGee*, Patrick M McCarthy

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter


According to recent data by the American Heart Association, Coronary Artery Disease (CAD) has a prevalence of 6.9% in the US population [1]. In 2002, 494,382 people died in the USA from the effects of CAD with a cost that reached 142.1 billion dollars in 2005 [1]. It is well established that patients with evidence of myocardial viability and target vessels for revascularization live longer with surgical revascularization as opposed to medical management especially if they have severe left ventricular dysfunction [2]. However, patients who reach end-stage ischemic-cardiomyopathy without evidence of viability do not benefit from revascularization [2]. This chapter discusses transplantation as treatment for these patients with end-stage ischemic cardiomyopathy.

Original languageEnglish (US)
Title of host publicationCoronary Artery Disease
Subtitle of host publicationNew Approaches without Traditional Revascularization
PublisherSpringer-Verlag London Ltd
Number of pages15
ISBN (Electronic)9781846287121
ISBN (Print)1846284600, 9781846284601
StatePublished - Apr 1 2012

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Cardiac transplantation for ischemic heart disease'. Together they form a unique fingerprint.

Cite this